Back to results
US 10,702,559 B2Granted
Methods and compositions relating to engineered microbial cells
AssigneeThe General Hospital Corporation
InventorsCammie Lesser, Analise Reeves
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods relating to engineered bacteria which have a modified Type 3 Secretion System (T3SS) which permits them to deliver proteins to the extracellular space (e.g., as opposed to the intracellular space of a target cell as done with a wild-type T3SS). In some embodiments, the engineered bacteria comprise a transgenic T3SS. In some embodiments, the delivered protein is non-native or transgenic with respect to the engineered bacteria.
Claims18
An engineered, non-pathogenic, gram negative microbial cell comprising:
- a) a first nucleic acid sequence comprising genes encoding a type 3 secretion system (T3SS)-derived extracellular secretion system (TDESS);
- wherein the TDESS comprises at least virulence regulon transcriptional activator (vir) B (virB);
- membrane expression of invasion plasmid antigens (mxi) G (mxiG);
- mxiH;
- mxiI;
- mxiJ;
- mxiK;
- mxiN;
- mxiL;
- mxiM;
- mxiD;
- mxiA;
- surface presentation antigens (spa) 47 (spa47);
- spa13;
- spa32;
- spa33;
- spa24;
- spa9;
- spa29;
- and spa40;
- b) a second nucleic acid sequence encoding an T3SS-compatible payload polypeptide;
- and not comprising or expressing at least one of
- invasion plasmid antigen (Ipa) B (IpaB);
- IpaD;
- or
- MxiC wherein the TDESS comprises polypeptides endogenous to a bacterium selected from the group consisting of:
- Shigella spp;
- Salmonella spp;
- enteropathogenic E. coli;
- and Yersinia spp.
27 more elements
Dependencies are inferred from the claim text.